财务业绩 - 第二季度总收入为1.267亿美元，同比增长34%[5] - Galafold收入为1.108亿美元，同比增长17%[7] - Pombiliti + Opfolda收入为1,585.2万美元，较第一季度增长44%[8] - 第二季度和上半年实现非GAAP盈利，预计下半年盈利将加速[12] - 公司第二季度净产品销售额为1.27亿美元，同比增长34.0%[34] - 第二季度毛利率为91.1%，同比提升2.9个百分点[34] - 第二季度非GAAP净利润为1,849万美元，上年同期为亏损2,026万美元[40] - 第二季度非GAAP每股收益为0.06美元，上年同期为亏损0.07美元[41] 财务指引 - 提高2024年总收入增长指引至26%-31%[14] - 提高2024年Galafold收入增长指引至14%-18%[14] - 2024年非GAAP经营费用指引收窄至3.45亿-3.6亿美元[14] 产品进展 - 获得瑞士批准上市Pombiliti + Opfolda，正在澳大利亚和加拿大申请监管审批[9] - 专注于2024年的四大战略重点:Galafold双位数收入增长、Pombiliti + Opfolda多市场成功上市、推进法布瑞和庞贝病的临床研究、实现全年非GAAP盈利[15] 财务状况 - 截至2024年6月30日，公司现金及现金等价物为2.09亿美元[36] - 截至2024年6月30日，公司存货为8,132万美元，较2023年年末增加36.3%[36] - 公司在2024年上半年进行了6,045万美元的重组费用[38] - 公司在2024年上半年录得880万美元的资产减值损失[38]

文章核心观点 - 美国最高法院裁定,北达科他州的一家便利店和加油站Corner Post公司可以在2021年对联邦储备委员会(联储)2011年制定的Regulation II提起诉讼,因为其损害是从2018年开始产生的,而不是从2011年规则颁布时开始[1][3][4] - 最高法院认为,行政程序法(APA)允许Corner Post在遭受Regulation II伤害的6年内提起诉讼,而不是从规则颁布之日算起[4][5] - 最高法院否认了政府提出的,Corner Post可以通过向联储申请修改Regulation II并对拒绝申请提起诉讼的说法,认为这不足以替代法院对该规则的独立审查[6] 根据相关目录分别进行总结 公司概况 - Corner Post公司是一家位于北达科他州的便利店和加油站,于2018年开始营业[3] - Corner Post公司于2021年对联储2011年颁布的Regulation II提起诉讼,称其遭受了过高的交易费用[3] 行业监管 - 联储于2011年颁布Regulation II,规定了借记卡交易的费用标准[3] - Corner Post公司认为Regulation II造成了其过高的交易费用[3] - 最高法院裁定Corner Post公司有权在遭受Regulation II伤害的6年内提起诉讼,而不是从规则颁布之日算起[4][5] - 最高法院否认了政府提出的,Corner Post可以通过向联储申请修改Regulation II并对拒绝申请提起诉讼的说法[6]

Washington, D.C., June 11, 2024 (GLOBE NEWSWIRE) -- The U.S. Court of Appeals for the Tenth Circuit has reversed a district court decision in Johnson v. Smith that upheld a Kansas state law authorizing intrusive warrantless searches for dog training and handling businesses. The New Civil Liberties Alliance filed an amicus curiae brief explaining that the warrantless-search law infringes the Appellants’ Fourth Amendment rights “to be secure in their persons, houses, papers, and effects, against unreasonable ...

Washington, D.C., June 05, 2024 (GLOBE NEWSWIRE) -- Today, the U.S. Court of Appeals for the Fifth Circuit issued a decision in National Association of Private Fund Managers v. Securities and Exchange Commission vacating SEC’s recent final rule restricting—and in some cases prohibiting—certain common contractual agreements between private investment funds and investment advisers. Following the New Civil Liberties Alliance amicus curiae brief’s advice, the Court declared that SEC exceeded its statutory autho ...

avdeev007 Today, we put rare disease concern Amicus Therapeutics (NASDAQ:FOLD) under the spotlight. The shares have recently slid under the $10 a share level, which seems too cheap given the company's revenue growth and movement towards profitability. We dig into recent quarterly results and update our investment analysis on this small-cap name in the paragraphs below. May 2024 Company Presentation Amicus Therapeutics is headquartered in Princeton, NJ. The company's product portfolio starts with Galafold. T ...

Amicus Therapeutics (FOLD) reported first-quarter 2024 adjusted loss of 2 cents per share, narrower than the Zacks Consensus Estimate of a loss of 6 cents. The company had incurred a loss of 6 cents per share in the year- ago quarter. The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti + Opfolda. Revenues in the reported quarter totaled $110.4 million, up 28% year over year on ...

For the quarter ended March 2024, Amicus Therapeutics (FOLD) reported revenue of $110.4 million, up 28% over the same period last year. EPS came in at -$0.02, compared to -$0.18 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $111.62 million, representing a surprise of -1.09%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being -$0.06. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Juris ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - CBO Jeff Castelli - CDO Simon Harford - CFO Conference Call Participants Anupam Rama - JPMorgan Ellie Merle - UBS Kristen Kluska - Cantor Fitzgerald Tazeen Ahmad - Bank of America Operator Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' First Quarter 2024 Financial Results Conference Cal ...

Exhibit 99.1 Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates 1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold Guidance on Continued Strong Demand Strong Pombiliti+ Opfolda Launch with Increasing Rate of Commercial Patient Starts Reiterating Full-Year Non-GAAP Profitability Projected in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, NJ, Ma ...